Travere Therapeutics Announces Planned Chief Executive Officer Transition View Full Press Release Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum